Cost-effectiveness analysis of second-line pharmacological treatment of acromegaly in Spain

Carmen Perala Health Economics and Outcomes Research Department, Pfizer S.L.U, Alcobendas (Madrid), SpainCorrespondence[email protected]
View further author information

Fernando Cordidob Endocrinology Department, Complejo Hospitalario Universitario A Coruña, and Universidad de A Coruña, A Coruña, SpainView further author information

Vicente Gimeno-Ballesterc Pharmacy Department, Hospital Miguel Servet, Zaragoza, SpainView further author information

Nuria Mird Medical Affairs Department, Pfizer S.L.U, Alcobendas (Madrid), SpainView further author information

Laura Sánchez-Cenizod Medical Affairs Department, Pfizer S.L.U, Alcobendas (Madrid), SpainView further author information

Citations (4)

Keep up to date with the latest research on this topic with citation updates for this article.